On 4th December 2023, the Intermediate People’s Court of Chongqing Municipality in China handed down its FRAND determination in the global 5G patent licensing dispute between patent owner Nokia and the Chinese implementer Oppo. The Finnish multinational has already confirmed that it will appeal the decision, which marks the first time a court has issued…

Yes and no, it seems. Well, yes and then no, if recent French decisions are anything to go by. In short, Hesitations Blues reign. This attitude is all the more interesting given that the question, which arose more especially in the FINGOLIMOD case, has been raised before several European courts, all of which are opposed…

The EPO has recently announced it will ‘accelerate its processing of parallel opposition proceedings if it is informed by the Unified Patent Court or a national court or competent authority of a contracting state that an infringement or revocation action relating to a European patent or a Unitary Patent has been instituted before it.’ It…

When the Unified Patent Court (“UPC”) endeavour was in the process of being designed back in the day, its architects presented the project as an example of a one-in-a-kind cosmopolitan litigation forum, the seat of patent judges and litigators from all cultures, skills, backgrounds, languages and walks of life. A cosmopolitan court that would set…

The facts of the case On 21 November 2023, Sir Anthony Mann of the London High Court handed down a judgment in the case of Emotional Perception AI Ltd v Comptroller-General of Patents, Designs and Trade Marks [2023] EWHC 2948 (Ch). This judgment addressed the question whether artificial neural networks (ANNs) are excluded subject matter…

The Unified Patent Court has announced that a new functionality is available on the CMS to download multiple documents at once from a given case. ‘Provided the need to access multiple documents from a case at once, the CMS now allows via a “Document Download” function, to download a bundle of documents. In order to…

On December 6, the Board of Directors (DICOL) of the Brazilian Food & Drug Agency (ANVISA) passed new regulations accepting an exemption to allow generics and branded generics (also called “similar” drugs) to remove patented uses from their labels – i.e., skinny labeling. The change will come into effect 60 days after the amended text…